Evidence map›Paper›PMID 30239611›Full record

ArticleBrain : a journal of neurology2018

White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease.

Miguel Ángel Araque Caballero, Marc Suárez-Calvet, Marco Duering, Nicolai Franzmeier, Tammie Benzinger, Anne M Fagan, Randall J Bateman, Clifford R Jack, Johannes Levin, Martin Dichgans and 16 more

Open access · hybridAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 1 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 1 synthesis or guideline pooled it, 180 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Locus coeruleus-entorhinal cortex tract integrity is linked to plasma tau and glial fibrillary acidic protein.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  13. Article
  14. Roles of TREM2 in Alzheimer's disease.Translational neurodegeneration · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Astrocyte and oligodendrocyte pathology in Alzheimer's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  20. Review

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 15 institutions in 5 countries.

Miguel Ángel Araque CaballeroInstitute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany.
Marc Suárez-CalvetGerman Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany.
Marco DueringInstitute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany.
Nicolai FranzmeierInstitute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany.
Tammie BenzingerDepartment of Radiology, Washington University in St Louis, St Louis, MO, USA.
Anne M FaganDepartment of Radiology, Washington University in St Louis, St Louis, MO, USA.
Randall J BatemanDepartment of Radiology, Washington University in St Louis, St Louis, MO, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Johannes LevinGerman Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany.
Martin DichgansInstitute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany.
Mathias JuckerHertie Institute for Clinical Brain Research, Tübingen, Germany and German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Celeste KarchKnight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.
Colin L MastersThe Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.
John C MorrisDepartment of Radiology, Washington University in St Louis, St Louis, MO, USA.
Michael WeinerUniversity of California at San Francisco, San Francisco, CA94143, USA.
Martin RossorDementia Research Centre, University College London, Queen Square, London, UK.
Nick C FoxDementia Research Centre, University College London, Queen Square, London, UK.
Jae-Hong LeeDepartment of Neurology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Stephen SallowayDepartment of Neurology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Adrian DanekGerman Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany.
Alison GoateDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Igor YakushevDepartment of Nuclear Medicine, Technical University of Munich, Munich, Germany.
Jason HassenstabDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Peter R SchofieldNeuroscience Research Australia, Barker Street Randwick, Sydney, Australia.
Christian HaassGerman Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany.
Michael EwersInstitute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany.
Ludwig-Maximilians-Universität München · DEWashington University in St. Louis · USHope Center for Neurological Disorders · USMunich Cluster for Systems Neurology · DEUK Dementia Research Institute · GBAsan Medical Center · KRBrown University · USFlorey Institute of Neuroscience and Mental Health · AUGerman Center for Neurodegenerative Diseases · DEHertie Institute for Clinical Brain Research · DEIcahn School of Medicine at Mount Sinai · USMayo Clinic in Arizona · USTechnical University of Munich · DEUniversity of California, San Francisco · USUNSW Sydney · AU

Funding

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
Imaging CoreU19AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2010 to 2025
$53.9M
Dominantly Inherited Alzheimer NetworkUF1AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2014 to 2017
$21.6M
Medical Research Council MR/009076/1Medical Research Council MR/L023784/1Medical Research Council MR/L023784/2Medical Research Council MR/M009106/1NIA NIH HHS U19 AG032438NIA NIH HHS U24 AG021886NIA NIH HHS UF1 AG032438
6 · The paper itself

Abstract

White matter alterations are present in the majority of patients with Alzheimer's disease type dementia. However, the spatiotemporal pattern of white matter changes preceding dementia symptoms in Alzheimer's disease remains unclear, largely due to the inherent diagnostic uncertainty in the preclinical phase and increased risk of confounding age-related vascular disease and stroke in late-onset Alzheimer's disease. In early-onset autosomal-dominantly inherited Alzheimer's disease, participants are destined to develop dementia, which provides the opportunity to assess brain changes years before the onset of symptoms, and in the absence of ageing-related vascular disease. Here, we assessed mean diffusivity alterations in the white matter in 64 mutation carriers compared to 45 non-carrier family non-carriers. Using tract-based spatial statistics, we mapped the interaction of mutation status by estimated years from symptom onset on mean diffusivity. For major atlas-derived fibre tracts, we determined the earliest time point at which abnormal mean diffusivity changes in the mutation carriers were detectable. Lastly, we assessed the association between mean diffusivity and cerebrospinal fluid biomarkers of amyloid, tau, phosphorylated-tau, and soluble TREM2, i.e. a marker of microglia activity. Results showed a significant interaction of mutations status by estimated years from symptom onset, i.e. a stronger increase of mean diffusivity, within the posterior parietal and medial frontal white matter in mutation carriers compared with non-carriers. The earliest increase of mean diffusivity was observed in the forceps major, forceps minor and long projecting fibres-many connecting default mode network regions-between 5 to 10 years before estimated symptom onset. Higher mean diffusivity in fibre tracts was associated with lower grey matter volume in the tracts' projection zones. Global mean diffusivity was correlated with lower cerebrospinal fluid levels of amyloid-β1-42 but higher levels of tau, phosphorylated-tau and soluble TREM2. Together, these results suggest that regionally selective white matter degeneration occurs years before the estimated symptom onset. Such white matter alterations are associated with primary Alzheimer's disease pathology and microglia activity in the brain.

Indexed as

AdultAlzheimer DiseaseBrainDiffusion Tensor ImagingFemaleHumansMaleMiddle AgedWhite Matter

Identifiers

PMID30239611
PMCPMC6158739
OpenAlexW2891943095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.